In our RA cohort, the 80AA genotype of RFC-1 G80A and the 2R/3R or 3R/3R genotypes of TYMS 2R/3R were more vulnerable to a good response to MTX treatment. This evidence concerns the gene TYMS and rheumatoid arthritis.